Litcius/Paper detail

Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

Ashkan Shoamanesh, Hardi Mundl, Eric E. Smith, Jaime Masjuán, Ivan Milanov, Teruyuki Hirano, Alina Agafina, Bruce Campbell, Valeria Caso, Jean‐Louis Mas, Qiang Dong, Peter Turčáni, Hanne Christensen, José M. Ferro, Roland Veltkamp, Robert Mikulík, Gian Marco De Marchis, Thompson Robinson, Robin Lemmens, Adam Stępień, Stefan Greisenegger, Risto O. Roine, László Csiba, Pooja Khatri, Jonathan M. Coutinho, Arne Lindgren, Andrew M. Demchuk, Pablo Colorado, Bodo Kirsch, Christoph Neumann, Laura Heenan, Lizhen Xu, Stuart J. Connolly, Robert G. Hart

2022The Lancet193 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboIschaemic strokeStroke (engine)Double blindInternal medicineAcute strokeCardiologyIschemiaTissue plasminogen activatorAlternative medicinePathologyMechanical engineeringEngineeringCoagulation, Bradykinin, Polyphosphates, and AngioedemaAtrial Fibrillation Management and OutcomesThyroid and Parathyroid Surgery
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial | Litcius